Our role in the society

Our task

We are the link between patients with special needs and the pharmaceutical market in cases where commercial drug providers are not able to deliver what is required.

Through our owner's directive, we have been commissioned to provide extemporaneous drugs and stock preparations to provide patients with special needs with individualized drugs.

It can for example be when:

  • approved drug with a desired substance is missing
  • correct strength and / or pharmaceutical form is lacking
  • the desired drug has such a short shelf life that it must be completed in connection with use
  • approved drug contains a substance to which the patient is hypersensitive


Prescription of extemporaneous drugs and stock preparations takes place in collaboration with specialist doctors, prescribers and authorities.

When the prescription of an extemporaneous drug becomes more extensive, it is called a stock preparation. Stock preparations are mass-produced, have a longer shelf life and can be delivered faster than extemporaneous drugs.

A sustainable APL

We strive to set a good example and be transparent in the context of sustainable enterprise. This is done through a continuous and open dialogue with all stakeholders, to ensure that we act in accordance with the directives and wishes presented. We are continuously working on measures that aim to reduce environmental impact and increase the effect in the value chain.

Contact

Visiting adress:

Prismavägen 2, Kungens Kurva


+46 10 447 96 00


Other contact information

About APL

Apotek Produktion & Laboratorier (APL) is one of Europe’s leading companies manufacturing extemporaneous drugs and stock preparations. We have a social mission from the Swedish government, but also work together with other pharmaceutical companies to create the greatest possible patient benefit. Our vision is that we will make a difference for patients with special needs. We are also an established contract manufacturer within Life Science in Scandinavia, where we deliver services within development and analysis. With more than 500 employees and five manufacturing units in Malmö, Gothenburg, Stockholm and Umeå, we develop drugs that improve and save lives.


Read more